Advertisement
Screener

Neuphoria Therapeutics Inc. (NEUP) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Neuphoria Therapeutics Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Neuphoria Therapeutics Inc. return tang equity for the quarter ending 2026-06-30 was -63.75%, a change of -60.18% year-over-year.
  • Neuphoria Therapeutics Inc. return tang equity for the quarter ending 2026-03-31 was -84.70%, a 355.04% decline year-over-year.
  • Neuphoria Therapeutics Inc. return tang equity for the quarter ending 2025-12-31 was -27.02%, a change of 126.77% year-over-year.
  • Neuphoria Therapeutics Inc. return tang equity for the quarter ending 2025-09-30 was -246.94%, a change of -114.39% year-over-year.
  • Neuphoria Therapeutics Inc. return tang equity for fiscal 2026 was -63.75%, a change of -60.18% from fiscal 2025.
  • Neuphoria Therapeutics Inc. return tang equity for fiscal 2025 was -3.57%, a change of 172.47% from fiscal 2024.
  • Neuphoria Therapeutics Inc. return tang equity for fiscal 2024 was -176.04%, a change of -15.47% from fiscal 2023.
  • Neuphoria Therapeutics Inc. return tang equity for fiscal 2023 was -160.57%.
Available history
2023-06-30 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-63.75%-$13.45M$21.1M
2026-03-31-84.70%-$17.43M$20.58M
2025-12-31-27.02%-$5.66M$20.96M
2025-09-30-246.94%-$9.47M$3.84M
2025-06-30-3.57%-$369,632.00$10.36M
2025-03-3133.21%$5.83M$17.55M
2024-12-31-153.79%-$8.21M$5.34M
2024-09-30-132.55%-$10.82M$8.17M
2024-06-30-176.04%-$15.49M$8.8M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-63.75%-$13.45M$21.1M
2025-06-30-3.57%-$369,632.00$10.36M
2024-06-30-176.04%-$15.49M$8.8M
2023-06-30-160.57%-$21.38M$13.32M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Marker Therapeutics, Inc. (MRKR)United States$0.020B-2.86
Cellectar Biosciences, Inc. (CLRB)United States$0.020B-1.03
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Rocket One Inc. (RKTO)United States$0.019B
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Lipocine Inc. (LPCN)United States$0.017B-1.79
PALATIN TECHNOLOGIES INC (PTN)United States$0.017B-5.36
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66